Jun 4, 2026 08:02AM
Jun 4, 2026 08:00AM
May 27, 2026 08:00AM
May 27, 2026 08:00AM
May 14, 2026 08:01AM
May 14, 2026 08:00AM
May 13, 2026 08:04AM MIRA Pharmaceuticals publishes peer-reviewed study on obesity drug candidate
May 13, 2026 08:00AM
Mar 23, 2026 09:03AM
Mar 23, 2026 09:00AM
Mar 4, 2026 08:00AM
Mar 4, 2026 08:00AM
Feb 3, 2026 07:31AM
Feb 3, 2026 07:30AM MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study
Oct 24, 2025 07:30AM
Oct 24, 2025 07:30AM
Oct 16, 2025 04:05PM
Oct 16, 2025 07:30AM
Oct 16, 2025 07:30AM
Sep 30, 2025 07:31AM
Sep 30, 2025 07:30AM MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction
Sep 22, 2025 08:02AM
Sep 22, 2025 08:00AM
Sep 16, 2025 07:30AM
Sep 16, 2025 07:30AM
Sep 15, 2025 04:06PM
Sep 12, 2025 07:30AM
Sep 12, 2025 07:30AM MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation
Aug 19, 2025 08:30AM
Aug 19, 2025 08:30AM
Aug 12, 2025 08:32AM
Aug 12, 2025 08:30AM
Jul 30, 2025 07:30AM
Jul 30, 2025 07:30AM
Jul 29, 2025 07:31AM MIRA Pharmaceuticals receives FDA clearance for Ketamir-2 neuropathic pain trial
Jul 29, 2025 07:30AM
Jul 11, 2025 08:00AM
Jul 11, 2025 08:00AM
Jul 3, 2025 08:02AM
Jul 3, 2025 08:00AM
Jun 30, 2025 08:00AM
Jun 25, 2025 08:00AM MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects
Jun 18, 2025 08:31AM
Jun 18, 2025 08:30AM
Jun 17, 2025 04:06PM
May 28, 2025 08:30AM
May 8, 2025 08:04AM
May 8, 2025 08:00AM
May 6, 2025 08:02AM Mira Pharma (MIRA) Reports No Brain Toxicity in FDA-Required Study of Ketamir-2
May 6, 2025 08:00AM

413,649 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All